Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma

Inclusion Criteria: * Histology confirmed ameloblastoma. * The patient was tested positive for BRAF V600E mutation. * Eligible patients must have evaluable lesions within the jaw that meet RECIST criteria. * Be 18 years or older. * Laboratory test results: ANC \> 1.5 x 109/L. PLT \> 99 x 109/L. Hemoglobin \>8 g/dL. Tbili \< 1.6 × ULN. AST, ALT and alkaline phosphate \< 2.6 times the upper limit of normal (ULN) . Serum creatinine ≤1.5 mg/dL, or serum creatinine \>1.5 mg/dL, creatinine clearance must be ≥50ml/min. PR / INR, PTT ≤ 1.3 × ULN, patients receiving anticoagulation therapy can participate in the trial if their INR is within the therapeutic range before randomization. * Patients of childbearing potential must agree to use effective contraception for at least 6 months after treatment with dabrafenib. * Be able to swallow and retain oral medications and must not have any clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome or major resection of the stomach or intestines. * The left ventricular ejection fraction is equal to or greater than normal within 1 month of enrollment. * Voluntarily sign the informed consent form and cooperate with the treatment. Exclusion Criteria: * Those who have used BRAF inhibitor treatment in the past. * Patients with invasive malignant tumors other than ameloblastoma within 3 years, excluding cancers with high cure rates, such as early cutaneous squamous cell carcinoma (T1 N0),…